Vaso (OTCMKTS:VASO) vs. Integra LifeSciences (NASDAQ:IART) Head to Head Review

Vaso (OTCMKTS:VASO) and Integra LifeSciences (NASDAQ:IART) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Vaso and Integra LifeSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaso	1.76%	5.66%	1.88%
Integra LifeSciences	-30.15%	17.42%	5.00%

Valuation and Earnings

This table compares Vaso and Integra LifeSciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaso	$89.10 million	0.36	$1.57 million	$0.01	17.98
Integra LifeSciences	$1.64 billion	0.66	-$516.47 million	($6.46)	-2.15

Vaso has higher earnings, but lower revenue than Integra LifeSciences. Integra LifeSciences is trading at a lower price-to-earnings ratio than Vaso, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

84.8% of Integra LifeSciences shares are held by institutional investors. 43.9% of Vaso shares are held by company insiders. Comparatively, 3.8% of Integra LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Vaso has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Vaso and Integra LifeSciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaso	0	0	0	0	0.00
Integra LifeSciences	3	3	0	0	1.50

Integra LifeSciences has a consensus price target of $12.75, suggesting a potential downside of 8.41%. Given Integra LifeSciences’ stronger consensus rating and higher probable upside, analysts plainly believe Integra LifeSciences is more favorable than Vaso.

Summary

Integra LifeSciences beats Vaso on 8 of the 13 factors compared between the two stocks.

About Vaso

Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.